Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 67
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Clin Exp Immunol ; 187(1): 146-159, 2017 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-27613250

RESUMO

A highly concentrated (20%) immunoglobulin (Ig)G preparation for subcutaneous administration (IGSC 20%), would offer a new option for antibody replacement therapy in patients with primary immunodeficiency diseases (PIDD). The efficacy, safety, tolerability and pharmacokinetics of IGSC 20% were evaluated in a prospective trial in Europe in 49 patients with PIDD aged 2-67 years. Over a median of 358 days, patients received 2349 IGSC 20% infusions at monthly doses equivalent to those administered for previous intravenous or subcutaneous IgG treatment. The rate of validated acute bacterial infections (VASBIs) was significantly lower than 1 per year (0·022/patient-year, P < 0·0001); the rate of all infections was 4·38/patient-year. Median trough IgG concentrations were ≥ 8 g/l. There was no serious adverse event (AE) deemed related to IGSC 20% treatment; related non-serious AEs occurred at a rate of 0·101 event/infusion. The incidence of local related AEs was 0·069 event/infusion (0·036 event/infusion, when excluding a 13-year-old patient who reported 79 of 162 total related local AEs). The incidence of related systemic AEs was 0·032 event/infusion. Most related AEs were mild, none were severe. For 64·6% of patients and in 94·8% of IGSC 20% infusions, no local related AE occurred. The median infusion duration was 0·95 (range = 0·3-4·1) h using mainly one to two administration sites [median = 2 sites (range = 1-5)]. Almost all infusions (99·8%) were administered without interruption/stopping or rate reduction. These results demonstrate that IGSC 20% provides an effective and well-tolerated therapy for patients previously on intravenous or subcutaneous treatment, without the need for dose adjustment.


Assuntos
Imunoglobulinas Intravenosas/uso terapêutico , Síndromes de Imunodeficiência/tratamento farmacológico , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Europa (Continente) , Feminino , Seguimentos , Humanos , Imunoglobulinas Intravenosas/administração & dosagem , Imunoglobulinas Intravenosas/farmacocinética , Infusões Subcutâneas , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Adulto Jovem
2.
J Clin Immunol ; 35(1): 26-31, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25491288

RESUMO

We describe here a novel c.137 + 5G > A intronic mutation in the SH2D1A gene of the signaling lymphocyte activation molecule (SLAM)-associated protein (SAP) in association with Epstein-Barr virus (EBV)-induced fatal infectious mononucleosis (FIM) in an 8-year-old male patient and his 3-year-old step brother. The mother and the maternal grandmother of the boys are healthy and heterozygous for this sequence variant. Genetic sequencing of blood-cell-derived cDNA in the younger patient revealed a 22 bp deletion in the SH2D1A cDNA. Immunoblot and flow cytometry analysis performed in this younger patient showed the lack of SAP protein expression in peripheral blood lymphocytes. These data suggest that the novel c.137 + 5G > A mutation results in loss of function of SAP protein and leads to typical X-linked lymphoproliferative disease phenotype. We propose that intron 1 and the c.137 + 5G may be the most frequent intronic hot spot for SH2D1A splicing mutation.


Assuntos
Peptídeos e Proteínas de Sinalização Intracelular/genética , Transtornos Linfoproliferativos/genética , Mutação , Sequência de Bases , Criança , Pré-Escolar , DNA Complementar/genética , Infecções por Vírus Epstein-Barr/etiologia , Infecções por Vírus Epstein-Barr/genética , Feminino , Humanos , Íntrons , Transtornos Linfoproliferativos/complicações , Masculino , Linhagem , Fenótipo , Deleção de Sequência , Proteína Associada à Molécula de Sinalização da Ativação Linfocitária
3.
J Clin Immunol ; 35(2): 199-205, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25663093

RESUMO

INTRODUCTION: Complement immunodeficiencies (excluding hereditary angioedema and mannose binding lectin deficiency) are rare. Published literature consists largely of case reports and small series. We collated data from 18 cities across Europe to provide an overview of primarily homozygous, rather than partial genotypes and their impact and management. METHODS: Patients were recruited through the ESID registry. Clinical and laboratory information was collected onto standardized forms and analyzed using SPSS software. RESULTS: Seventy-seven patients aged 1 to 68 years were identified. 44 % presented in their first decade of life. 29 % had C2 deficiency, defects in 11 other complement factors were found. 50 (65 %) had serious invasive infections. 61 % of Neisseria meningitidis infections occurred in patients with terminal pathway defects, while 74 % of Streptococcus pneumoniae infections occurred in patients with classical pathway defects (p < 0.001). Physicians in the UK were more likely to prescribe antibiotic prophylaxis than colleagues on the Continent for patients with classical pathway defects. After diagnosis, 16 % of patients suffered serious bacterial infections. Age of the patient and use of prophylactic antibiotics were not associated with subsequent infection risk. Inflammatory/autoimmune diseases were not seen in patients with terminal pathway, but in one third of patients classical and alternative pathway defects. CONCLUSION: The clinical phenotypes of specific complement immunodeficiencies vary considerably both in terms of the predominant bacterial pathogen, and the risk and type of auto-inflammatory disease. Appreciation of these phenotypic differences should help both immunologists and other specialists in their diagnosis and management of these rare and complex patients.


Assuntos
Proteínas do Sistema Complemento/deficiência , Proteínas do Sistema Complemento/genética , Síndromes de Imunodeficiência/epidemiologia , Síndromes de Imunodeficiência/genética , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Ativação do Complemento/genética , Ativação do Complemento/imunologia , Proteínas do Sistema Complemento/imunologia , Consanguinidade , Bases de Dados Factuais , Gerenciamento Clínico , Europa (Continente)/epidemiologia , Feminino , Genótipo , Humanos , Síndromes de Imunodeficiência/diagnóstico , Síndromes de Imunodeficiência/terapia , Lactente , Masculino , Pessoa de Meia-Idade , Adulto Jovem
4.
Br J Dermatol ; 170(3): 617-24, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24251354

RESUMO

BACKGROUND: Filaggrin (FLG) deficiency is a well-known predisposing factor for the development of atopic dermatitis (AD). Decreased FLG expression can be the result of haploinsufficiency or severe inflammation, which can cause acquired FLG alterations. FLG mutations are related to several clinical and laboratory parameters of AD; however, some recent data seem to contradict these associations. OBJECTIVES: Our aim was to determine which clinical and biochemical parameters are connected to FLG haploinsufficiency and which ones are also associated with acquired FLG alterations due to severe skin symptoms in patients with AD. METHODS: We introduced a novel classification of patients with AD, based on FLG mutations and SCORAD (SCORing Atopic Dermatitis). Based on these parameters, we created three groups of patients with AD: mild-to-moderate wild-type (A), severe wild-type (B) and severe mutant (C). In all groups, we assessed laboratory and clinical parameters and performed immunohistochemical analyses. RESULTS: Groups B and C contained patients with equally severe symptoms based on the SCORAD. The two severe groups did not differ significantly with respect to barrier-specific parameters, whereas group A had significantly better results for the barrier function measurements. However, significant differences were detected between groups B and C with respect to the allergic sensitization-specific parameters. CONCLUSIONS: These findings suggest that skin barrier function correlates with the severity of skin inflammation and can be equally impaired in patients with FLG mutant- and wild-type AD with severe symptoms. Nevertheless, our results also suggest that patients with FLG mutant-type AD may have a higher risk of allergic sensitization compared with patients with the wild-type.


Assuntos
Dermatite Atópica/genética , Proteínas de Filamentos Intermediários/genética , Mutação/genética , Adolescente , Adulto , Criança , Pré-Escolar , Citocinas/metabolismo , Ensaio de Imunoadsorção Enzimática , Feminino , Proteínas Filagrinas , Genótipo , Humanos , Proteínas de Filamentos Intermediários/deficiência , Masculino , Pele/metabolismo , Perda Insensível de Água/genética , Adulto Jovem , Linfopoietina do Estroma do Timo
5.
J Clin Immunol ; 33(8): 1341-8, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24158785

RESUMO

PURPOSE: Almost all patients with autoimmune polyendocrine syndrome (APS)-I have high titer neutralizing autoantibodies to type I interferons (IFN), especially IFN-ω and IFN-α2, whatever their clinical features and onset-ages. About 90 % also have antibodies to interleukin (IL)-17A, IL-17F and/or IL-22; they correlate with the chronic mucocutaneous candidiasis (CMC) that affects ~90 % of patients. Our aim was to explore how early the manifestations and endocrine and cytokine autoantibodies appear in young APS-I patients. That may hold clues to very early events in the autoimmunization process in these patients. METHODS: Clinical investigations and autoantibody measurements in 13 APS-I patients sampled before age 7 years, and 3 pre-symptomatic siblings with AIRE-mutations in both alleles. RESULTS: Antibody titers were already high against IFN-α2 and IFN-ω at age 6 months in one sibling-8 months before onset of APS-I-and also against IL-22 at 7 months in another (still unaffected at age 5 years). In 12 of the 13 APS-I patients, antibody levels were high against IFN-ω and/or IL-22 when first tested, but only modestly positive against IFN-ω in one patient who had only hypo-parathyroidism. Endocrine organ-specific antibodies were present at age 6 months in one sibling, and as early as 36 and 48 months in two of the six informative subjects. CONCLUSION: This is the first study to collate the onset of clinical features, cytokine and endocrine autoantibodies in APS-I infants and siblings. The highly restricted early autoantibody responses and clinical features they show are not easily explained by mere loss of broad-specific self-tolerance inducing mechanisms, but hint at some more sharply focused early event(s) in autoimmunization.


Assuntos
Autoanticorpos/sangue , Citocinas/imunologia , Poliendocrinopatias Autoimunes/diagnóstico , Poliendocrinopatias Autoimunes/imunologia , Adolescente , Adulto , Autoanticorpos/biossíntese , Criança , Pré-Escolar , Diagnóstico Precoce , Feminino , Humanos , Lactente , Interferon-alfa/imunologia , Interleucina-17/imunologia , Interleucinas/imunologia , Masculino , Poliendocrinopatias Autoimunes/metabolismo , Síndrome , Adulto Jovem , Interleucina 22
6.
Scand J Immunol ; 75(2): 227-30, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21958324

RESUMO

X-linked hyper-IgM syndrome (XHIGM) is a primary immunodeficiency disorder (PID) caused by mutation in the gene encoding the CD40 ligand (CD40L) expressed on activated T cells. Prenatal genotyping in carriers with twin pregnancies is more challenging than in women with singleton pregnancies. In addition, women with twin pregnancies may decide on selective termination for which the risk of loss of the healthy foetus may exceed 7%. We report here on a family affected by XHIGM. Diagnosis of the disease was made in a male patient as late as 33 years of age. After family screening, the sister of the proband conceived male twins in two consecutive pregnancies. In the first pregnancy, one of the male foetuses was hemizygous for the c.521A>G (Q174R) mutation in the CD40L gene. In the second pregnancy, ultrasound scan showed one foetus to have exencephaly and karyotyping revealed this foetus to have trisomy 18. Several options were discussed, but the parents decided on selective termination in both pregnancies. The interventions were successful in both cases, and the mother now has two healthy sons. This report demonstrates the way in which advanced technologies in molecular medicine and obstetric interventions may assist families with decisions about possible selective termination in case of life-threatening molecular or chromosomal disorders. Diagnosis of CD40L deficiency at the age of 33 years in the proband was striking and indicated that PIDs are still neglected as disease entities in the evaluation of patients with recurrent severe infectious diseases.


Assuntos
Ligante de CD40/deficiência , Síndrome de Imunodeficiência com Hiper-IgM Tipo 1/diagnóstico , Síndrome de Imunodeficiência com Hiper-IgM Tipo 1/genética , Gravidez de Gêmeos/genética , Trissomia/diagnóstico , Trissomia/genética , Aborto Eugênico , Adulto , Ligante de CD40/genética , Ligante de CD40/imunologia , Cromossomos Humanos Par 18/genética , Cromossomos Humanos Par 18/imunologia , Diagnóstico Tardio , Feminino , Idade Gestacional , Humanos , Síndrome de Imunodeficiência com Hiper-IgM Tipo 1/imunologia , Síndrome de Imunodeficiência com Hiper-IgM Tipo 1/patologia , Recém-Nascido , Cariotipagem , Masculino , Mutação , Linhagem , Gravidez , Gravidez de Gêmeos/imunologia , Diagnóstico Pré-Natal , Linfócitos T/imunologia , Linfócitos T/patologia , Trissomia/imunologia , Trissomia/patologia , Síndrome da Trissomía do Cromossomo 18
7.
Clin Exp Immunol ; 161(3): 512-7, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20550545

RESUMO

We studied the efficacy, safety and pharmacokinetic profiles of Intratect®, a recently developed polyvalent intravenous immunoglobulin (IVIG) preparation. Fifty-one patients (aged 6-48 years) with primary immunodeficiencies (PID) and established replacement therapy using a licensed IVIG were enrolled and treated for 12 months with Intratect®. Retrospective patient data served as prestudy controls. The primary efficacy variable was the annual rate of acute serious bacterial infection (ASBI) per patient. Secondary parameters were annual rate of acute relevant infection (ARI), days with antibiotic use, fever, absence from school/work and hospitalization. The average IVIG dose was 0·49 g/kg, with an average infusion rate of 2·4 ml/kg/h. The annual ASBI rate/patient was 0·02 and ARIs were detected 128 times during the 630 adverse events in 40 patients, specified mainly as bronchitis, sinusitis, respiratory tract infection, rhinitis and pharyngitis. The annual rate of respiratory ARIs/patient was 2·0 and the rates/patient for days with fever >38°C, school/work absence and hospitalization were 1·81, 3·99 and 0·36, respectively. A total of 630 adverse events (AEs) were observed in 50 of 51 (98·0%) of patients. In 46 of 51 patients the AEs were not related to infusion. Pharmacokinetic studies after the first infusion revealed a mean elimination half-life of 50·8 ± 30·3 days. During this study, 19 of 649 (2·9%) IgG trough levels were below 6 g/l, better than that of reference IVIGs during the 6 months before study start (10 of 201). These data suggest that Intratect® is a well tolerated, safe and effective IgG concentrate for the treatment of patients with PID.


Assuntos
Imunoglobulinas Intravenosas/farmacocinética , Imunoglobulinas Intravenosas/uso terapêutico , Síndromes de Imunodeficiência/tratamento farmacológico , Adolescente , Adulto , Área Sob a Curva , Bronquite/induzido quimicamente , Criança , Esquema de Medicação , Feminino , Humanos , Imunoglobulinas Intravenosas/efeitos adversos , Síndromes de Imunodeficiência/metabolismo , Síndromes de Imunodeficiência/patologia , Fatores Imunológicos/administração & dosagem , Fatores Imunológicos/farmacocinética , Fatores Imunológicos/uso terapêutico , Infecções/induzido quimicamente , Infusões Intravenosas , Masculino , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Estudos Prospectivos , Sinusite/induzido quimicamente , Resultado do Tratamento , Adulto Jovem
8.
J Intern Med ; 266(6): 502-6, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19930097

RESUMO

Primary immunodeficiencies (PIDs) are often recognized in adults, either because of delayed diagnosis of a paediatric illness, or increasingly because of the recognition of adult onset forms of these diseases. Moreover, a growing fraction of children diagnosed with PIDs reach adulthood. It has become clear that many of these conditions affect various organs and therefore will be referred to professionals from various fields of internal medicine. It is well known that infectious diseases, allergy, auto-immunity and cancer may result from PIDs. Surprisingly, other clinical manifestations were recently found to reflect inborn errors of immunity. Ground-breaking discoveries suggest that atypical haemolytic uraemic syndrome, Crohn's disease, and alveolar proteinosis may actually be manifestations of novel PIDs.


Assuntos
Doença de Crohn/genética , Fator Estimulador de Colônias de Granulócitos e Macrófagos/deficiência , Síndrome Hemolítico-Urêmica/genética , Síndromes de Imunodeficiência/genética , Proteinose Alveolar Pulmonar/genética , Adulto , Doença de Crohn/imunologia , Diagnóstico Tardio , Predisposição Genética para Doença , Genótipo , Síndrome Hemolítico-Urêmica/imunologia , Humanos , Síndromes de Imunodeficiência/complicações , Síndromes de Imunodeficiência/imunologia , Fenótipo , Proteinose Alveolar Pulmonar/imunologia
9.
Clin Genet ; 74(1): 68-74, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-18479478

RESUMO

Wiskott-Aldrich syndrome (WAS) is an X-linked primary immunodeficiency disorder associated with microthrombocytopenia, eczema, autoimmunity and predisposition to malignant lymphoma. Although rare, few cases of somatic mosaicism have been published in WAS patients to date. We here report on two Ukrainian siblings who were referred to us at the age of 3 and 4 years, respectively. Both patients suffered from severe WAS caused by a nonsense mutation in exon 1 of the WAS gene. In both siblings, flow cytometric analysis revealed the presence of Wiskott-Aldrich syndrome protein (WASp)-positive and WASp-negative cell populations among T and B lymphocytes as well as natural killer (NK) cells. In contrast to previously described cases of revertant mosaicism in WAS, molecular analyses in both children showed that the WASp-positive T cells, B cells, and NK cells carried multiple different second-site mutations, resulting in different missense mutations. To our knowledge, this is the first report describing somatic mosaicism in WAS patients caused by several independent second-site mutations in the WAS gene.


Assuntos
Proteína da Síndrome de Wiskott-Aldrich/genética , Síndrome de Wiskott-Aldrich/genética , Pré-Escolar , Códon sem Sentido , Humanos , Masculino , Mosaicismo , Irmãos
10.
J Clin Invest ; 91(6): 2596-601, 1993 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-8390485

RESUMO

In contrast to its macrophage-activating capacity, IFN-gamma downregulates expression of the macrophage mannose receptor (MMR), which mediates uptake of Candida and other microorganisms. We found that IFN-gamma induced a concentration-dependent increase in the capacity of human monocyte-derived macrophages to ingest and kill both opsonized and unopsonized Candida albicans and to release superoxide anion upon stimulation with Candida. Mannan or mannosylated albumin inhibited this activated uptake of unopsonized Candida, but glucan did not. Addition of mAb to complement receptor (CR) 3 did not inhibit ingestion; macrophages that lacked CR3 (leukocyte adhesion defect) showed normal upregulation of ingestion by IFN-gamma. The increased candidacidal activity of IFN-gamma-activated macrophages was associated with reduced expression of MMR by a mean of 79% and decreased pinocytic uptake of 125I-mannosylated BSA by 73%; K(uptake) of pinocytosis was not changed. Exposure of resident macrophages to unopsonized Candida did not elicit a transient increase in intracellular free Ca2+ ([Ca2+]i); macrophages activated by IFN-gamma expressed a brisk increase in [Ca2+]i on exposure to Candida. These data suggest that macrophage activation by IFN-gamma can enhance resistance to C. albicans infection in spite of downregulation of the MMR, perhaps through enhanced coupling of the MMR to microbicidal functions.


Assuntos
Candida albicans , Interferon gama/farmacologia , Lectinas Tipo C , Macrófagos/imunologia , Lectinas de Ligação a Manose , Receptores de Superfície Celular , Receptores Imunológicos/metabolismo , Cálcio/metabolismo , Relação Dose-Resposta a Droga , Humanos , Macrófagos/efeitos dos fármacos , Receptor de Manose , Fagocitose , Superóxidos/metabolismo
12.
J Invest Dermatol ; 117(2): 205-13, 2001 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-11511295

RESUMO

Human keratinocytes are known to kill Candida albicans in vitro, but the mechanism of killing is not yet understood. Here, we demonstrate that spontaneous, ultraviolet-B-light-induced, alpha-melanocyte-stimulating-hormone-induced, and interleukin-8-induced Candida killing by keratinocytes can be inhibited with mannan and mannosylated bovine serum albumin (Man-BSA). A polyclonal goat serum raised against the human macrophage mannose receptor stained suprabasal keratinocytes, but no staining was observed on keratinocytes with a monoclonal antibody (mAb15) specific for the human macrophage mannose receptor. Mannose-affinity chromatography of keratinocyte extract isolated a 200 kDa protein, and on the Western blot the goat antiserum reacted with a 200 kDa protein. In radioligand binding studies, the binding of 125I-Man-BSA to human keratinocytes was inhibited by mannan in a concentration-dependent manner. Analysis of the binding revealed a single class keratinocyte mannose receptor with a KD of 1.4 x 10(-8) M and a Bmax of 1 x 10(4) binding sites per cell. The binding of 125I-Man- BSA to keratinocytes proved to be time-dependent, acid-precipitable, and Ca2+- and trypsin-sensitive. After trypsinization the receptors underwent a rapid recovery at 37 degrees C. These results demonstrate the presence of mannose receptor on human keratinocytes, and its active involvement in the killing of Candida albicans.


Assuntos
Candida albicans/imunologia , Candidíase/imunologia , Queratinócitos/metabolismo , Queratinócitos/microbiologia , Lectinas Tipo C , Lectinas de Ligação a Manose , Receptores de Superfície Celular/biossíntese , Anticorpos Monoclonais , Western Blotting , Cálcio/metabolismo , Candidíase/metabolismo , Adesão Celular , Quelantes/farmacologia , Reações Cruzadas , Ácido Egtázico/farmacologia , Citometria de Fluxo , Humanos , Imuno-Histoquímica , Técnicas In Vitro , Radioisótopos do Iodo , Queratinócitos/citologia , Leucócitos/imunologia , Leucócitos/metabolismo , Leucócitos/microbiologia , Mananas/farmacologia , Manose/farmacocinética , Receptor de Manose , Ensaio Radioligante , Receptores de Superfície Celular/análise , Receptores de Superfície Celular/imunologia , Albumina Sérica/farmacocinética , Pele/citologia , Pele/microbiologia
13.
J Immunol Methods ; 57(1-3): 353-61, 1983 Feb 25.
Artigo em Inglês | MEDLINE | ID: mdl-6827110

RESUMO

A micro-assay has been developed for the separate evaluation of phagocytosis and intracellular killing of Staphylococcus aureus by human monocytes and granulocytes. The minimal number of phagocytes required for the investigation of these functional activities of phagocytic cells has been established by performing phagocytosis and intracellular killing experiments at various cell concentrations, bacteria-to-cell ratios, and volumes. The results of these experiments revealed that phagocytosis can be measured in a reliable way, at bacteria-to-cell ratios of 5:1 and 1:1 (cell concentration 5 x 10(6)/ml), in a suspension of 200 microliters. The rate of intracellular killing by monocytes and granulocytes can also be measured with a total phagocytic suspension of 200 microliters and a cell concentration of 5 x 10(6)/ml. From these results it can be concluded that for an independent determination of the phagocytosis and intracellular killing of micro-organisms, 400 microliters of 5 x 10(6) phagocytes/ml is required, i.e., a total of 2 x 10(6) phagocytes. This number of granulocytes can be obtained from 1-2 ml of blood; for monocytes 4-8 ml of blood is required.


Assuntos
Atividade Bactericida do Sangue , Granulócitos/imunologia , Monócitos/imunologia , Staphylococcus aureus/imunologia , Citotoxicidade Imunológica , Humanos , Fagocitose
14.
DNA Cell Biol ; 15(8): 617-24, 1996 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-8769563

RESUMO

A chimeric antibody-like molecule consisting of the human myeloperoxidase (rMPO) fused to the second and third constant-sequence (CH2 and CH3) Fc domains of human immunoglobulin G-1 has been constructed and expressed in Chinese hamster ovary (CHO) cells. This fusion molecule was designed to combine the binding specificity of Fc with the antimicrobial properties of rMPO. The rMPO-Fc fusion dimerized through the Fc fragment, while retaining the enzymatic activity of rMPO. The chimeric molecule was glycosylated and most of the propeptide was eliminated, indicating a better processing of the polypeptide than for rMPO alone. Both rMPO and rMPO-Fc bound to and were internalized by macrophage-like U937 promonocytic cells. Unexpectedly, the chimera failed to bind to the Fc receptor but interacted with a higher affinity than rMPO with the same binding sites. The presence of the Fc fragment in the chimera, in addition, did not extend the plasma half-life of the fusion protein. In vitro, rMPO-Fc exhibited a stronger killing effect than rMPO toward Candida albicans in the presence of either H202 alone or human macrophages. In vivo, rMPO-Fc similarly conferred a better protection than rMPO in a lethal model of murine cowdriosis. These properties could be related to the Fc-induced dimerization of the fusion protein in CHO cells.


Assuntos
Candida albicans/efeitos dos fármacos , Hidropericárdio/prevenção & controle , Fragmentos Fc das Imunoglobulinas/imunologia , Ativação de Macrófagos/imunologia , Peroxidase/farmacocinética , Animais , Sequência de Bases , Células CHO , Candida albicans/imunologia , Linhagem Celular , Cricetinae , Glicosilação , Humanos , Fragmentos Fc das Imunoglobulinas/genética , Imunoglobulina G/imunologia , Cadeias gama de Imunoglobulina/genética , Cadeias gama de Imunoglobulina/imunologia , Camundongos , Dados de Sequência Molecular , Peso Molecular , Monócitos/imunologia , Peroxidase/química , Peroxidase/genética , Peroxidase/metabolismo , Peroxidase/farmacologia , Peroxidase/uso terapêutico , Receptores Fc/metabolismo , Proteínas Recombinantes de Fusão/química , Proteínas Recombinantes de Fusão/metabolismo , Proteínas Recombinantes de Fusão/farmacocinética , Proteínas Recombinantes de Fusão/uso terapêutico
15.
J Med Microbiol ; 32(1): 19-24, 1990 May.
Artigo em Inglês | MEDLINE | ID: mdl-2342083

RESUMO

The opsonic requirement for phagocytosis and killing and cell-surface hydrophobicity of five strains of Staphylococcus saprophyticus isolated from clinical sources were studied. Phagocytosis and killing of bacteria by human granulocytes were measured in suspension. Bacterial aggregating cell-surface hydrophobicity was determined by salt aggregation, and the absorptive hydrophobicity was measured by hydrophobic interaction chromatography. All strains were well opsonised by pooled normal human serum 10%. Ingestion of these bacteria could be detected to a variable extent in the absence of extracellular opsonins; heat-inactivated serum 10% or intravenous IgG concentrate 1 mg/ml improved phagocytosis of all strains. Significantly increased rates of both the ingestion and killing of one of the five strains occurred in the presence of IgG or in the absence of opsonins, compared to those found with each of the other four. This particular strain had significantly stronger adsorptive surface hydrophobicity than the other four strains, and with all strains there was a correlation between hydrophobicity and phagocytosis by granulocytes in the absence of opsonins.


Assuntos
Coagulase/farmacologia , Granulócitos/fisiologia , Novobiocina/farmacologia , Proteínas Opsonizantes/fisiologia , Fagocitose , Staphylococcus/efeitos dos fármacos , Humanos , Propriedades de Superfície
16.
Acta Paediatr Suppl ; 91(438): 117-9, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12477274

RESUMO

AIM: To describe functional and molecular characteristics of interferon-gamma (IFN-gamma) activation in neonatal mononuclear phagocytes (monocytes and macrophages). METHODS AND RESULTS: Exposure of cord and adult macrophages to IFN-gamma gave quantitatively different results in Candida killing, as well as in release of superoxide anion (O2-). At concentrations of 100 U ml(-1) IFN-gamma, maximal increase in these functions with adult macrophages was achieved, whereas no enhancement of killing and O2- release by cord macrophages could be detected. Expression of IFN-gamma receptors was comparable on cord and adult cells and specific binding of [125I]IFN-gamma to cord monocytes and macrophages was even higher compared with adult cells. By flow cytometry, elements of IFN-gamma receptor-mediated signaling in cord and adult monocytes and macrophages were studied. Monoclonal antibodies against the native form of the signal transducer and activator of transcription-1 (STAT-1) revealed comparable expression of this protein in cord and adult macrophages. However, STAT-1 phosphorylation in response to IFN-gamma was significantly decreased in neonatal monocytes (p < 0.05) and macrophages (p < 0.01) compared with adult cells. CONCLUSION: These data suggest deficient cytokine receptor signaling in neonatal mononuclear phagocytes exposed to IFN-gamma.


Assuntos
Sangue Fetal/citologia , Recém-Nascido/imunologia , Interferon gama/farmacologia , Ativação de Macrófagos/imunologia , Receptores de Interferon/biossíntese , Receptores de Interferon/imunologia , Adulto , Fatores Etários , Candida albicans/imunologia , Estudos de Casos e Controles , Células Cultivadas , Meios de Cultura , Feminino , Humanos , Imunidade Celular/fisiologia , Masculino , Monócitos/imunologia , Fagocitose/imunologia , Sensibilidade e Especificidade , Receptor de Interferon gama
17.
Orv Hetil ; 136(40): 2169-72, 1995 Oct 01.
Artigo em Húngaro | MEDLINE | ID: mdl-7566951

RESUMO

Hyper-IgM syndrome associating with severe neutropenie presenting in irregularis cycles was diagnosed in a 3-year-old male patient. His elder brother died of sepsis which appeared as a consequence of dysgammaglobulinaemia and neutropenia at the age of 9. We could not achieve a parmanent good result with the monthly immunoglobulin substitution and supportive treatment. The candida infection of the gingiva and of the oral mucous membrane expanded to the esophagus resulting in its complete occlusion and temporarily a gastrostomy was needed to feed him. We started with the recombinant human granulocyta colony stimulating factor (rh-G-CSF) treatment at the age of 6. We tried several ways of applying and finally the 10 micrograms/kg/dose given subcutan, for 5-10 days from the nadir of the neutropenic cycle seemed the most effective. The rh-G-CSF treatment resulted in an increase of ANC and the complete resolution of gingivostomatitis. The incidents of infections, the requirement of antibiotics and the duration of hospitalisation were markedly reduced. The consequent improvement in his physical condition made it possible to finally resolve the esophageal stricture surgically. We have not observed any neutropenic cycle since the end of the 14 month rh-G-CSF treatment. Though the medicine was discontinued there has been no recidiva for more than 22 months.


Assuntos
Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Hipergamaglobulinemia/complicações , Imunoglobulina M , Neutropenia/complicações , Candidíase Bucal/tratamento farmacológico , Candidíase Bucal/microbiologia , Criança , Pré-Escolar , Relação Dose-Resposta a Droga , Esofagite/tratamento farmacológico , Esofagite/microbiologia , Gengivite/tratamento farmacológico , Gengivite/microbiologia , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Humanos , Hipergamaglobulinemia/tratamento farmacológico , Hipergamaglobulinemia/imunologia , Injeções Subcutâneas , Masculino , Neutropenia/tratamento farmacológico , Proteínas Recombinantes , Síndrome
18.
Orv Hetil ; 142(46): 2557-61, 2001 Nov 18.
Artigo em Húngaro | MEDLINE | ID: mdl-11770174

RESUMO

Protective immunity to intracellular bacteria such as mycobacteria and salmonella depends on intact cell-mediated immunity. Major effector mechanisms of cell-mediated immunity involve activation of macrophages by T helper-1 cytokines, particularly interferon-gamma. Patients with genetic deficiency of T helper-1 cytokines (IFN-gamma, IL-12) or T helper-1 cytokine receptors (IFN-gamma receptor, IL-12 receptor) are susceptible to infections with poorly pathogenic mycobacteria, and salmonella, suggesting that T helper-1 cytokines are essential in host defense against these pathogens. This review reports on the genetic and clinical characteristics of primary deficiencies of interferon-gamma activation pathways.


Assuntos
Interferon gama/metabolismo , Receptores de Interferon/metabolismo , Transdução de Sinais/imunologia , Humanos , Interferon gama/imunologia , Interleucina-12/metabolismo , Macrófagos/metabolismo , Receptores de Interferon/genética , Receptores de Interferon/imunologia , Receptores de Interleucina/metabolismo , Receptores de Interleucina-12 , Cromossomo X/genética
19.
Orv Hetil ; 132(44): 2421-3, 1991 Nov 03.
Artigo em Húngaro | MEDLINE | ID: mdl-1945383

RESUMO

D-penicillamine was introduced to treat neonatal hyperbilirubinaemia in 1973 and to prevent retinopathy of prematurity in 1980. In this study we investigated the renal and liver functions of neonates treated with DPA and the in vitro effect of the drug on superoxide anion generation and beta-glucuronidase release as well as on phagocytic and intracellular killing activation on human peripheral blood granulocytes. Our data concerning the renal and liver functions before and after 3 to 4 days DPA treatment reveal no pathological change during short-term administration in the neonatal period. Furthermore, none of the examined DPA concentrations influenced the phagocytic or killing activity of neutrophils.


Assuntos
Hiperbilirrubinemia/tratamento farmacológico , Penicilamina/farmacologia , Humanos , Técnicas In Vitro , Recém-Nascido , Rim/efeitos dos fármacos , Fígado/efeitos dos fármacos , Penicilamina/administração & dosagem , Fagócitos/efeitos dos fármacos , Retinopatia da Prematuridade/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA